At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
combination nivolumab and ipilimumabbiological
Likely dose
combination nivolumab and ipilimumab 3 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Combination Immunotherapy With Ipilimumab and Nivolumab in Patients With Advanced Non-small Cell Lung Cancer Resistant to Anti-PD-1-axis Therapy
In Brief
A Phase 2 clinical trial evaluating combination nivolumab and ipilimumab for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The investigators propose a trial to evaluate if the addition of ipilimumab to nivolumab after primary or acquired resistance to anti- programmed death 1 (PD-1) axis therapy can lead to objective radiographic tumor regression.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesUnited States
CollaboratorsBristol-Myers Squibb
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartJul 2017
First PostedAug 2017
Primary CompletionJan 2022
TodayJul 2026
First PostedAug 25, 2017
Enrollment StartJul 20, 2017
Primary CompletionJan 14, 2022
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 8.9 years ago
Interventions
combination nivolumab and ipilimumabbiological
Combination therapy with nivolumab 3 mg/kg administered intravenously (IV) every 2 weeks, with ipilimumab 1 mg/kg administered IV every 6 weeks.